Pharmacyclics Announces $21 Billion Acquisition by AbbVie

The Wall Street Journal and The New York Times DealBook reported that Olshan client Pharmacyclics announced it was being acquired by Abbvie for $261.25 per share in a combination of cash and stock with a total transaction value of approximately $21 billion. Olshan served as special counsel to Pharmacyclics on certain issues relating to the transaction.